HIV co-infections (HBV, HCV, TB) US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for HIV co-infections (HBV, HCV, TB). These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
HIV co-infections (HBV, HCV, TB) US Medical PG Question 1: A scientist is researching the long term effects of the hepatitis viruses on hepatic tissue. She finds that certain strains are oncogenic and increase the risk of hepatocellular carcinoma. However, they appear to do so via different mechanisms. Which of the following answer choices correctly pairs the hepatitis virus with the correct oncogenic process?
- A. Hepatitis A virus - chronic inflammation
- B. Hepatitis C virus - chronic inflammation
- C. Hepatitis E virus - integration of viral DNA into host hepatocyte genome
- D. Hepatitis B virus - integration of viral DNA into host hepatocyte genome (Correct Answer)
- E. Hepatitis A virus - integration of viral DNA into host hepatocyte genome
HIV co-infections (HBV, HCV, TB) Explanation: ***Hepatitis B virus - integration of viral DNA into host hepatocyte genome***
- **Hepatitis B virus (HBV)** is a **DNA virus** that can integrate its genetic material into the host hepatocyte genome, leading to genomic instability and promoting oncogenesis.
- This integration, along with chronic inflammation and the production of viral regulatory proteins, contributes significantly to the development of **hepatocellular carcinoma (HCC)**.
*Hepatitis A virus - chronic inflammation*
- **Hepatitis A virus (HAV)** is an **RNA virus** that causes **acute hepatitis** but does not lead to chronic infection or chronic inflammation.
- Due to its acute and self-limiting nature, HAV is **not associated with hepatocellular carcinoma**.
*Hepatitis C virus - integration of viral DNA into host hepatocyte genome*
- **Hepatitis C virus (HCV)** is an **RNA virus** and therefore does not integrate its DNA into the host genome (as it has no DNA phase).
- HCV causes HCC primarily through **chronic inflammation**, **fibrosis**, and **cirrhosis**, not DNA integration.
*Hepatitis E virus - integration of viral DNA into host hepatocyte genome*
- **Hepatitis E virus (HEV)** is an **RNA virus** that typically causes acute, self-limiting hepatitis and does not integrate its genetic material into the host genome.
- While HEV can cause chronic infection in immunocompromised individuals, it is **not generally recognized as an oncogenic virus** leading to HCC.
*Hepatitis A virus - integration of viral DNA into host hepatocyte genome*
- **Hepatitis A virus (HAV)** is an **RNA virus**, meaning it does not have a DNA stage and therefore cannot integrate DNA into the host genome.
- HAV causes **acute, self-limiting infections** and is definitively **not associated with hepatocellular carcinoma**.
HIV co-infections (HBV, HCV, TB) US Medical PG Question 2: A 52-year-old male patient with chronic alcoholism presents to an ambulatory medical clinic, where the hepatologist elects to perform comprehensive hepatitis B screening, in addition to several other screening and preventative measures. Given the following choices, which serologic marker, if positive, would indicate the patient’s immunity to the hepatitis B virus?
- A. HBeAb
- B. HBeAg
- C. HBsAb (Correct Answer)
- D. HBsAg
- E. HBcAb
HIV co-infections (HBV, HCV, TB) Explanation: ***HBsAb***
- A positive **HBsAb** (Hepatitis B surface antibody) indicates immunity to hepatitis B virus, either from successful **vaccination** or **recovery from past infection**.
- This antibody provides **protective immunity** against future HBV infection and is the definitive marker of immunity.
*HBeAb*
- **HBeAb** (Hepatitis B e antibody) indicates **seroconversion** from HBeAg during chronic HBV infection, suggesting lower viral replication.
- It does **not confer immunity** against the virus itself and only reflects a phase of chronic infection.
*HBeAg*
- **HBeAg** (Hepatitis B e antigen) indicates **active viral replication** with high infectivity during ongoing hepatitis B infection.
- Its presence signifies a **replicative phase** of infection and increased risk of transmission to others.
*HBsAg*
- **HBsAg** (Hepatitis B surface antigen) indicates **active hepatitis B infection**, whether acute or chronic.
- This antigen is the **first serologic marker** to appear following exposure and confirms presence of the virus.
*HBcAb*
- **HBcAb** (Hepatitis B core antibody) indicates **previous or current exposure** to hepatitis B virus.
- It does **not differentiate** between acute, chronic, or resolved infection and does not confer protective immunity.
HIV co-infections (HBV, HCV, TB) US Medical PG Question 3: A 30-year-old woman presents with generalized fatigue, joint pain, and decreased appetite. She says that symptoms onset a year ago and have not improved. The patient’s husband says he has recently noticed that her eyes and skin are yellowish. The patient denies any history of smoking or alcohol use, but she admits to using different kinds of intravenous illicit drugs during her college years. The patient is afebrile and vital signs are within normal limits. Physical examination is unremarkable, except for moderate scleral icterus. A polymerase chain reaction (PCR) of a blood sample is positive for a viral infection that reveals a positive-sense RNA virus, that is small, enveloped, and single-stranded. The patient is started on a drug that resembles a purine RNA nucleotide. She agrees not to get pregnant before or during the use of this medication. Which of the following is the drug that was most likely given to this patient?
- A. Sofosbuvir
- B. Cidofovir
- C. Ribavirin (Correct Answer)
- D. Simeprevir
- E. Interferon-alpha
HIV co-infections (HBV, HCV, TB) Explanation: ***Ribavirin***
- The patient's history of **intravenous drug use**, fatigue, joint pain, decreased appetite, and **scleral icterus** are highly suggestive of **chronic Hepatitis C virus (HCV) infection**. The description of the virus as a **small, enveloped, single-stranded positive-sense RNA virus** confirms HCV. The patient is started on a drug that resembles a **purine RNA nucleotide** and is instructed not to get pregnant, which is characteristic of Ribavirin.
- **Ribavirin** is a **guanosine analog** that interferes with viral RNA synthesis and is known to be **teratogenic**, necessitating strict contraception during and after treatment.
*Sofosbuvir*
- While **Sofosbuvir** is used to treat Hepatitis C and is a **nucleotide analog** (specifically a uridine analog), it is a **prodrug** that mimics a uridine nucleotide, not a purine, and it is **not associated with the severe teratogenicity** that requires a two-contraception rule like Ribavirin.
- Sofosbuvir is a **direct-acting antiviral (DAA)** that inhibits the HCV RNA-dependent RNA polymerase, but the description of a purine RNA nucleotide points away from this drug.
*Cidofovir*
- **Cidofovir** is a **cytosine nucleotide analog** primarily used to treat **cytomegalovirus (CMV)** retinitis in HIV/AIDS patients.
- It works by inhibiting viral DNA polymerase, and it is **not used for Hepatitis C infection**.
*Simeprevir*
- **Simeprevir** is an **HCV protease inhibitor**, not a nucleotide analog. It specifically targets the **NS3/4A protease** of the Hepatitis C virus.
- Although it is an effective DAA for HCV, its mechanism of action and class are different from the described "purine RNA nucleotide."
*Interferon-alpha*
- **Interferon-alpha** was historically used to treat Hepatitis C, but it is a **cytokine** that modulates the immune response, not a nucleoside/nucleotide analog.
- Its use has largely been replaced by more effective and better-tolerated direct-acting antivirals due to significant side effects and lower efficacy.
HIV co-infections (HBV, HCV, TB) US Medical PG Question 4: A 24-year-old man comes to the physician for a routine health maintenance examination. He feels well. He has type 1 diabetes mellitus. His only medication is insulin. He immigrated from Nepal 2 weeks ago . He lives in a shelter. He has smoked one pack of cigarettes daily for the past 5 years. He has not received any routine childhood vaccinations. The patient appears healthy and well nourished. He is 172 cm (5 ft 8 in) tall and weighs 68 kg (150 lb); BMI is 23 kg/m2. His temperature is 36.8°C (98.2°F), pulse is 72/min, and blood pressure is 123/82 mm Hg. Examination shows a healed scar over his right femur. The remainder of the examination shows no abnormalities. A purified protein derivative (PPD) skin test is performed. Three days later, an induration of 13 mm is noted. Which of the following is the most appropriate initial step in the management of this patient?
- A. Administer isoniazid for 9 months
- B. Collect sputum sample for culture
- C. Perform interferon-γ release assay
- D. Obtain a chest x-ray (Correct Answer)
- E. Perform PCR of the sputum
HIV co-infections (HBV, HCV, TB) Explanation: ***Obtain a chest x-ray***
- A **positive PPD test** (13 mm induration in a patient with risk factors) indicates possible **latent tuberculosis infection (LTBI)**, but before initiating treatment, it's crucial to rule out **active tuberculosis (TB)**.
- A chest x-ray is the initial step to screen for signs of active disease, such as **infiltrates, cavitations**, or **lymphadenopathy**, which would necessitate a different treatment regimen than LTBI.
*Administer isoniazid for 9 months*
- This is a standard treatment for **LTBI**, but it should only be initiated after **active TB has been ruled out**.
- Treating active TB with LTBI monotherapy would be inadequate and could lead to **drug resistance**.
*Collect sputum sample for culture*
- **Sputum culture** is essential for diagnosing active pulmonary TB and for **drug susceptibility testing**, but it's typically performed *after* a chest x-ray suggests active disease.
- In a patient with a positive PPD and no symptoms, starting with sputum cultures without imaging is not the most appropriate first step.
*Perform interferon-γ release assay*
- **Interferon-γ release assays (IGRAs)**, such as QuantiFERON-TB Gold or T-Spot.TB, are alternative tests for detecting **M. tuberculosis infection**.
- While IGRAs can be used in place of or in conjunction with PPD, they also do not differentiate between latent and active infection, so a chest x-ray would still be required.
*Perform PCR of the sputum*
- **PCR (nucleic acid amplification test)** of sputum rapidly detects *M. tuberculosis* DNA and is a valuable tool for diagnosing **active TB**, especially in cases where rapid results are needed.
- However, like sputum culture, it is usually reserved for situations where there is a strong suspicion of active disease based on clinical symptoms or imaging findings.
HIV co-infections (HBV, HCV, TB) US Medical PG Question 5: A 35-year-old man with no known past medical history presents to his physician because he is applying for a job as a healthcare worker, which requires screening for the hepatitis B virus (HBV). The patient states that he is in good health and denies any symptoms. His vital signs and physical exam are unremarkable. Labs are drawn, and the patient's HBV serology shows the following:
HBsAg: positive
anti-HBsAg antibody: negative
anti-HBcAg IgM: negative
anti-HBcAg IgG: positive
HBeAg: negative
anti-HBeAg antibody: positive
Which of the following best describes this patient's results?
- A. Immune due to previous infection
- B. Chronically infected, low infectivity (Correct Answer)
- C. Immune due to previous vaccination
- D. Acutely infected
- E. Chronically infected, high infectivity
HIV co-infections (HBV, HCV, TB) Explanation: ***Chronically infected, low infectivity***
- The presence of **HBsAg positive** for more than 6 months indicates **chronic HBV infection**. The presence of **anti-HBeAg antibody** and **negative HBeAg** suggests **low viral replication activity** and thus low infectivity.
- **HBeAg negativity** along with positivity for **HBV DNA** (if tested, though not provided here) would further differentiate this state as **"HBeAg-negative chronic hepatitis B,"** which typically implies lower, but still present, infectivity compared to HBeAg-positive chronic infection.
*Immune due to previous infection*
- Immunity due to previous infection is characterized by **negative HBsAg** and **positive anti-HBsAg antibody**, along with **positive anti-HBcAg IgG**.
- This patient, however, is **HBsAg positive** and **anti-HBsAg antibody negative**, ruling out resolved infection.
*Immune due to previous vaccination*
- Immunity due to vaccination is characterized by **negative HBsAg**, **positive anti-HBsAg antibody**, and **negative anti-HBcAg antibody** (both IgM and IgG).
- This patient has **positive HBsAg** and **positive anti-HBcAg IgG**, indicating either current or past infection, not vaccination-induced immunity.
*Acutely infected*
- **Acute infection** is characterized by **positive HBsAg**, **negative anti-HBsAg antibody**, and typically **positive anti-HBcAg IgM**.
- This patient has **negative anti-HBcAg IgM**, which makes acute infection unlikely, as IgM antibodies are present early in acute infection.
*Chronically infected, high infectivity*
- **High infectivity** in chronic HBV infection is typically indicated by **positive HBsAg** and **positive HBeAg**, often with high levels of HBV DNA.
- This patient is **HBeAg negative** and **anti-HBeAg antibody positive**, indicating a lower level of viral replication and thus lower infectivity.
HIV co-infections (HBV, HCV, TB) US Medical PG Question 6: A 52-year-old woman comes to the physician because of abdominal discomfort, anorexia, and mild fatigue. She has systemic lupus erythematosus and takes hydroxychloroquine. She does not drink alcohol or use illicit drugs. Physical examination shows no abnormalities. Laboratory studies show:
Alanine aminotransferase 455 U/L
Aspartate aminotransferase 205 U/L
Hepatitis B surface antigen positive
Hepatitis B surface antibody negative
Hepatitis B envelope antigen positive
Hepatitis B core antigen IgG antibody positive
Which of the following is the most appropriate pharmacotherapy for this patient?
- A. Acyclovir
- B. Tenofovir (Correct Answer)
- C. Pegylated interferon-alpha
- D. Dolutegravir
- E. Sofosbuvir
HIV co-infections (HBV, HCV, TB) Explanation: ***Tenofovir***
- This patient has **chronic active hepatitis B infection**, as indicated by **positive HBsAg**, **HBeAg**, and elevated liver enzymes. Antiviral therapy with **tenofovir** is highly effective and appropriate to suppress viral replication.
- The coexistence of **Systemic Lupus Erythematosus (SLE)** and **hydroxychloroquine** use increases the importance of managing HBV, as immunosuppression can lead to viral reactivation; tenofovir effectively targets the virus without significant interactions.
*Acyclovir*
- **Acyclovir** is an antiviral medication primarily used to treat infections caused by **herpes simplex virus (HSV)** and **varicella-zoster virus (VZV)**.
- It has **no efficacy** against hepatitis B virus (HBV) and therefore would not be appropriate for this patient's condition.
*Pegylated interferon-alpha*
- **Pegylated interferon-alpha** is an immunomodulatory agent used to treat chronic hepatitis B and C; however, it has a **less favorable side effect profile** and is often reserved for patients who cannot tolerate or respond to nucleoside/nucleotide analogs.
- The patient's underlying **SLE** could be **exacerbated by interferon**, making tenofovir a safer and more appropriate first-line choice given its better tolerability and potent antiviral effect.
*Dolutegravir*
- **Dolutegravir** is an **integrase inhibitor** used in the treatment of **HIV infection**.
- It has **no antiviral activity** against the hepatitis B virus and is therefore not indicated for this patient's condition.
*Sofosbuvir*
- **Sofosbuvir** is a direct-acting antiviral agent primarily used to treat **chronic hepatitis C virus (HCV) infection**.
- It is **not effective** against hepatitis B virus (HBV) and would not be the correct treatment for this patient.
HIV co-infections (HBV, HCV, TB) US Medical PG Question 7: A 27-year-old man presents with a 2-week history of fever, malaise, and occasional diarrhea. On physical examination, the physician notes enlarged inguinal lymph nodes. An HIV screening test is positive. Laboratory studies show a CD4+ count of 650/mm3. This patient is most likely currently in which of the following stages of HIV infection?
- A. Chronic HIV infection
- B. Asymptomatic HIV infection
- C. AIDS
- D. Acute HIV infection (Correct Answer)
- E. Clinical latency stage
HIV co-infections (HBV, HCV, TB) Explanation: ***Acute HIV infection***
- The symptoms (fever, malaise, diarrhea, enlarged lymph nodes) and the timeframe (2 weeks) are classic for **acute retroviral syndrome**, which occurs 2-4 weeks after initial HIV infection.
- A positive HIV screening test with a relatively high **CD4+ count** (650/mm³) is typical during this initial phase before significant immune deterioration.
- Also known as **primary HIV infection**, this stage represents the body's initial immune response to the virus.
*Chronic HIV infection*
- This stage is typically characterized by a **longer duration** (years) with often **asymptomatic periods** or mild, non-specific symptoms, and a gradually declining CD4+ count.
- While enlarged lymph nodes can persist, the acute onset of fever and malaise with only 2 weeks of symptoms points away from this more stable, quiescent phase.
*Asymptomatic HIV infection*
- This phrase is often used interchangeably with the **clinical latency stage** of chronic HIV infection, where the patient has no symptoms related to HIV despite ongoing viral replication.
- The presence of fever, malaise, diarrhea, and lymphadenopathy described in the case clearly indicates a **symptomatic phase**, not an asymptomatic one.
*AIDS*
- **AIDS (Acquired Immunodeficiency Syndrome)** is defined by a CD4+ T cell count below 200 cells/mm³ or the presence of an AIDS-defining opportunistic infection or malignancy.
- The patient's CD4+ count of 650/mm³ is well above the threshold for AIDS diagnosis.
*Clinical latency stage*
- This stage, also called **chronic asymptomatic HIV infection**, typically lasts 8-10 years without treatment and is characterized by minimal or no symptoms.
- Patients in clinical latency have **declining but not yet critically low CD4+ counts** and generally feel well.
- The acute presentation with fever, malaise, and the **2-week timeframe** clearly indicates a much earlier stage of infection.
HIV co-infections (HBV, HCV, TB) US Medical PG Question 8: A 52-year-old man presents to his physician after his routine screening revealed that he has elevated liver enzymes. He complains of occasional headaches during the past year, but otherwise feels well. The patient reports that he was involved in a serious car accident in the 1980s. He does not smoke or drink alcohol. He has no history of illicit intravenous drug use. He does not currently take any medications and has no known allergies. His father had a history of alcoholism and died of liver cancer. The patient appears thin. His temperature is 37.8°C (100°F), pulse is 100/min, and blood pressure is 110/70 mm Hg. The physical examination reveals no abnormalities. The laboratory test results show the following:
Complete blood count
Hemoglobin 14 g/dL
Leukocyte count 10,000/mm3
Platelet count 146,000/mm3
Comprehensive metabolic profile
Glucose 150 mg/dL
Albumin 3.2 g/dL
Total bilirubin 1.5 mg/dL
Alkaline phosphatase 75 IU/L
AST 95 IU/L
ALT 73 IU/L
Other lab tests
HIV negative
Hepatitis B surface antigen negative
Hepatitis C antibody positive
HCV RNA positive
HCV genotype 1
A liver biopsy is performed and shows mononuclear infiltrates localized to portal tracts that reveal periportal hepatocyte necrosis. Which of the following is the most appropriate next step in management?
- A. Peginterferon alpha therapy
- B. Interferon and ribavirin therapy
- C. Sofosbuvir and ledipasvir therapy (Correct Answer)
- D. Tenofovir and entecavir therapy
- E. Tenofovir and velpatasvir therapy
HIV co-infections (HBV, HCV, TB) Explanation: ***Sofosbuvir and ledipasvir therapy***
- This patient has chronic **Hepatitis C (HCV) infection** (HCV antibody positive, HCV RNA positive). **Sofosbuvir/ledipasvir** is an effective **direct-acting antiviral (DAA)** regimen for **genotype 1 HCV**, which is indicated for treatment-naïve patients without cirrhosis.
- The liver biopsy findings of **mononuclear infiltrates** and **periportal necrosis** confirm active hepatitis and the need for antiviral treatment to prevent progression to cirrhosis.
*Peginterferon alpha therapy*
- **Peginterferon alpha** was historically used for HCV, but its use has largely been replaced by **DAAs** due to significant side effects and lower efficacy.
- This therapy is associated with numerous adverse effects, including **flu-like symptoms**, **depression**, and **bone marrow suppression**.
*Interferon and ribavirin therapy*
- This combination was a standard treatment for HCV before the advent of DAAs, but it is associated with a high burden of **side effects** like **hemolytic anemia** (from ribavirin) and **flu-like symptoms** (from interferon).
- Given the availability of highly effective and well-tolerated DAAs, this regimen is no longer considered first-line for chronic HCV.
*Tenofovir and entecavir therapy*
- **Tenofovir** and **entecavir** are antiviral medications primarily used for the treatment of **chronic Hepatitis B (HBV) infection**.
- This patient's **Hepatitis B surface antigen is negative**, ruling out chronic HBV infection as the primary issue requiring these specific drugs.
*Tenofovir and velpatasvir therapy*
- While **velpatasvir** is a DAA used for HCV, its combination with **tenofovir** is not a standard HCV treatment for genotype 1.
- **Tenofovir** is primarily an anti-HBV drug; for HCV, velpatasvir is typically combined with **sofosbuvir** (as in Epclusa) for pan-genotypic coverage.
HIV co-infections (HBV, HCV, TB) US Medical PG Question 9: A 45-year-old man presents for follow-up to monitor his chronic hepatitis C treatment. The patient was infected with hepatitis C genotype 1, one year ago. He has been managed on a combination of pegylated interferon-alpha and ribavirin, but a sustained viral response has not been achieved. Past medical history is significant for non-alcoholic fatty liver disease for the last 5 years. Which of the following, if added to the patient’s current treatment regimen, would most likely benefit this patient?
- A. Emtricitabine
- B. Entecavir
- C. Simeprevir (Correct Answer)
- D. Tenofovir
- E. Telbivudine
HIV co-infections (HBV, HCV, TB) Explanation: ***Simeprevir***
- Simeprevir is a **first-generation direct-acting antiviral (DAA)**, specifically a **protease inhibitor (NS3/4A inhibitor)**, highly effective against **HCV genotype 1**.
- Adding simeprevir to a regimen of **pegylated interferon-alpha and ribavirin** significantly increases the likelihood of achieving a **sustained virologic response** for patients who previously failed interferon-based therapy.
- **Note:** While this triple therapy approach was standard practice historically, current guidelines (as of 2024-2025) favor **interferon-free DAA combination regimens** (such as sofosbuvir/ledipasvir or glecaprevir/pibrentasvir) as first-line treatment for HCV genotype 1. However, among the options provided, simeprevir remains the only appropriate HCV-specific antiviral agent.
*Emtricitabine*
- This is a **nucleoside reverse transcriptase inhibitor (NRTI)** primarily used in the treatment of **HIV infection** and sometimes for hepatitis B.
- It has **no significant role** in the treatment of **hepatitis C viral infection**.
*Entecavir*
- Entecavir is an **antiviral agent** specifically used for the treatment of **chronic hepatitis B virus (HBV)** infection.
- It has **no established efficacy** against the **hepatitis C virus (HCV)**.
*Tenofovir*
- Tenofovir is a **nucleotide reverse transcriptase inhibitor** primarily used for treating **HIV infection** and **chronic hepatitis B virus (HBV)** infection.
- It is **not effective** against **hepatitis C virus (HCV)**.
*Telbivudine*
- Telbivudine is an **oral antiviral agent** indicated specifically for the treatment of **chronic hepatitis B virus (HBV)** infection.
- It does **not have antiviral activity** against the **hepatitis C virus (HCV)**.
HIV co-infections (HBV, HCV, TB) US Medical PG Question 10: A 57-year-old man comes to the physician because of generalized malaise, yellowish discoloration of the eyes, and pruritus on the back of his hands that worsens when exposed to sunlight for the past several months. He has not seen a physician in 15 years. Physical examination shows scleral icterus and mild jaundice. There is a purpuric rash with several small vesicles and hyperpigmented lesions on the dorsum of both hands. The causal pathogen of this patient's underlying condition was most likely acquired in which of the following ways?
- A. Ingestion of raw shellfish
- B. Inhalation of spores
- C. Needlestick injury (Correct Answer)
- D. Bathing in freshwater
- E. Sexual contact
HIV co-infections (HBV, HCV, TB) Explanation: ***Needlestick injury***
- The jaundice, scleral icterus, pruritus, and **purpuric rash worsened by sunlight** (suggesting **Porphyria Cutanea Tarda**) are highly indicative of **chronic Hepatitis C virus infection**.
- **Hepatitis C** is primarily transmitted through **blood-to-blood contact**, with **needlestick injuries** and intravenous drug use being the most common routes.
*Ingestion of raw shellfish*
- **Hepatitis A virus** and **Vibrio vulnificus** can be acquired this way, but they typically cause acute, self-limiting illness or severe sepsis, respectively, not chronic liver disease with porphyria.
- **Hepatitis A** does not lead to chronic hepatitis or the dermatological manifestations described.
*Inhalation of spores*
- **Inhalation of spores** is associated with fungal infections like **histoplasmosis** or **coccidioidomycosis**, which do not typically cause chronic hepatitis, jaundice, pruritus, or porphyria cutanea tarda.
- These infections primarily affect the lungs, though disseminated forms can occur, they do not match the presented symptoms.
*Bathing in freshwater*
- **Bathing in freshwater** can transmit pathogens like **Leptospira** or **Schistosoma**, causing leptospirosis or schistosomiasis, respectively.
- These infections present with different clinical pictures and are not associated with chronic hepatitis, jaundice, or porphyria cutanea tarda.
*Sexual contact*
- While **Hepatitis C** can be transmitted sexually, this route is significantly **less efficient** than blood-to-blood contact.
- **Hepatitis B** is more commonly associated with sexual transmission and can also cause chronic liver disease, but the presence of **Porphyria Cutanea Tarda** is a characteristic extrahepatic manifestation strongly associated with **chronic Hepatitis C infection**.
- Given the clinical presentation, **needlestick injury or intravenous drug use** (blood-borne transmission) is the most likely route of HCV acquisition.
More HIV co-infections (HBV, HCV, TB) US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
